Myriad Genetics Common Stock Net 2010-2024 | MYGN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Myriad Genetics common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Myriad Genetics common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$158.3B
Bristol Myers Squibb (BMY)	$119.4B
Vertex Pharmaceuticals (VRTX)	$116.1B
Gilead Sciences (GILD)	$112.4B
CSL (CSLLY)	$87.2B
Regeneron Pharmaceuticals (REGN)	$81.1B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$36.2B
Alnylam Pharmaceuticals (ALNY)	$31.6B
BioNTech SE (BNTX)	$27.1B
Biogen (BIIB)	$23B
Illumina (ILMN)	$22.2B
BeiGene (BGNE)	$18.6B
Moderna (MRNA)	$15.8B
Incyte (INCY)	$13.8B
Genmab (GMAB)	$13.7B
Insmed (INSM)	$13.1B
BioMarin Pharmaceutical (BMRN)	$12.2B
Bio-Techne Corp (TECH)	$11.3B
Vaxcyte (PCVX)	$11B
Sarepta Therapeutics (SRPT)	$10.9B
Exelixis (EXEL)	$10.2B
Exact Sciences (EXAS)	$9.8B
QIAGEN (QGEN)	$9.8B
Revolution Medicines (RVMD)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$9.3B
Intra-Cellular Therapies (ITCI)	$9.1B
Repligen (RGEN)	$8B
Ascendis Pharma (ASND)	$7.9B